Floatz logo

cd19-cart

B Acute Lymphoblastic Leukemia

PersonGen BioTherapeutics (Suzhou) Co., Ltd.Cell therapyEarly Phase 1Dormant
C
36/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
73/ 100

Competitive context

141 Active assets in the B Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Washington
Phase 3BBB
VINCRISTINE SULFATE
City of Hope Medical Center
Phase 3BB
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
City of Hope Medical Center
Phase 3BB
MERCAPTOPURINE ANHYDROUS
SWOG Cancer Research Network
Phase 3BB
PEGASPARGASE
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

cd19-cart is also rated in:

acute lymphoblastic leukemiaDormant
CCC
Indicative ·
53 / 100
View asset →
mantle cell lymphomaDormant
C
Indicative ·
34 / 100
View asset →
follicular lymphomaDormant
C
Indicative ·
34 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →